Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

3rd TIGIT Axis Therapies

Evvnt Promotion / evvnt
-
07.12.2022 - 08.12.2022  Virtual Event, USA
Time: 8:00 am to 5:00 pm
 
Temi della conferenza
As immuno-oncology drug development transforms cancer treatment paradigms, preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.
Scientific organizer
Hanson Wade
Annotazioni
Speakers: Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies, David Wald, Associate Professor, Case Western Reserve University, Leonie Meima, Vice President Business Development, Coherus Biosciences
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/1234464-2?pid=4832
Ms. Ellie Saunders
 
Categorie
Oncologia
Lingua
Inglese
Quote del Congresso
Conference Only - Industry Pricing - On the Day : USD 2299.00, Conference Only - Academic Pricing - On the Day: USD 2099.00, Conference Only - Service and Solution Provider Pricing - On the Day: USD 2799.00
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Österreichische Akademie der ÄrzteHilfswerk AustriaÄrztekammer für WiennewTreeAGEM - Arbeitsgemeinschaft Ethnologie und MedizinEuropean Public Health Association (EUPHA)Österreichisches Rotes KreuzAnästhesie in Entwicklungsländern e. V.